November 20, 2010 -- Novo Nordisk will spend up to $100 million to expand its Beijing R&D center; Roche will cut 4,800 jobs globally but expand in China; the Monitor Group said China will be the global leader in life science discovery and innovation by 2020; Guizhou Bailing will invest $113 million to produce TCM of China's Miao minority; Sichuan Kelun Pharma will acquire an 85% stake in Zhejiang Guojing Pharma for $37 million; Lansen Pharma will purchase 20% of Zhejiang Starry Pharma for $24 million; Andon Health will spend $8 million to set up a US subsidiary; China's Ministry of Health plans a crackdown on bribery in the medical supply chain; and Sihuan Pharma has struck a deal to distribute a vasodilator for Benxi Leilong Pharma. More details....
Stock Symbols: (NYSE: NVO) (VX: ROG) (SHEX: 002424) (SHEX: 002422) (HKEX: 0503) (SHEX: 002432) (HKEX: 0460)
